CAR T-Cell Therapy for Multiple Myeloma Pipeline Summary

DelveInsight’s, “CAR T-Cell Therapy for Multiple Myeloma - Pipeline Insight, 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in CAR T-Cell Therapy for Multiple Myeloma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

CAR T-Cell Therapy for Multiple Myeloma: Understanding

CAR T-Cell Therapy for Multiple Myeloma: Overview

Chimeric antigen receptor (CAR) T-cell therapy is an advanced form of personalized immunotherapy that utilizes a patient’s own T cells to specifically recognize and eliminate cancer cells. In multiple myeloma, it has emerged as a transformative treatment option for patients with relapsed or refractory disease who have progressed despite receiving standard therapies such as proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Most currently available CAR T-cell therapies are directed against B-cell maturation antigen (BCMA), a protein that is highly expressed on malignant plasma cells, making it an effective therapeutic target.

The treatment process begins with leukapheresis, during which T cells are collected from the patient’s blood and transported to a specialized manufacturing facility. These cells are genetically engineered to express a chimeric antigen receptor (CAR) capable of recognizing BCMA on myeloma cells. The modified T cells are then expanded in large numbers over several weeks to produce an adequate therapeutic dose before being returned for clinical use.

Prior to CAR T-cell infusion, patients receive lymphodepleting chemotherapy, most commonly with fludarabine and cyclophosphamide, to reduce existing immune cells and create an environment that supports CAR T-cell expansion and persistence. Once infused, the engineered T cells circulate throughout the body, bind to BCMA-expressing myeloma cells, and induce targeted immune-mediated destruction. This highly specific mechanism enables potent antitumor activity while minimizing damage to healthy tissues.

Clinical trials have shown that BCMA-directed CAR T-cell therapy achieves high overall response rates, typically ranging from 70% to 98%, with many patients attaining complete or very good partial responses. Although these responses are often deep and rapid, maintaining long-term remission remains challenging, as many patients eventually relapse within 12–18 months. Ongoing research is focused on improving CAR T-cell persistence and durability through next-generation constructs, dual-targeting strategies, and memory-enriched T-cell products, while optimizing the management of treatment-related toxicities such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).

"CAR T-Cell Therapy for Multiple Myeloma- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the CAR T-Cell Therapy for Multiple Myeloma pipeline landscape is provided which includes the disease overview and CAR T-Cell Therapy for Multiple Myeloma treatment guidelines. The assessment part of the report embraces, in depth CAR T-Cell Therapy for Multiple Myeloma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, CAR T-Cell Therapy for Multiple Myeloma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence CAR T-Cell Therapy for Multiple Myeloma R&D. The therapies under development are focused on novel approaches to treat/improve CAR T-Cell Therapy for Multiple Myeloma.

CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs Chapters

This segment of the CAR T-Cell Therapy for Multiple Myeloma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

CAR T-Cell Therapy for Multiple Myeloma Emerging Drugs

AZD0120: AstraZeneca

AZD0120 is an investigational autologous dual-targeting CAR T-cell therapy directed against B-cell maturation antigen (BCMA) and CD19 for the treatment of multiple myeloma. The dual-antigen design aims to improve the depth and durability of response by targeting both malignant plasma cells and disease-associated precursor B cells, potentially reducing antigen escape. AZD0120 is being evaluated in the Phase III DURGA-4 trial in patients with relapsed/refractory multiple myeloma, where it is being compared with standard-of-care regimens, while earlier Phase I studies continue to assess its safety and preliminary efficacy. The trial's primary endpoints include progression-free survival (PFS) and minimal residual disease (MRD)-negative complete response, supporting its development as a next-generation CAR T-cell therapy for multiple myeloma.

SENL103: Hebei Senlang Biotechnology Inc., Ltd.

SENL103 is an investigational autologous BCMA-targeted CAR T-cell therapy being developed for the treatment of relapsed or refractory multiple myeloma (R/R MM). It is designed to selectively recognize and eliminate BCMA-expressing malignant plasma cells, offering a targeted immunotherapy approach for patients who have received multiple prior lines of therapy. SENL103 is currently being evaluated in a Phase I/II, open-label, single-arm clinical trial to assess its safety, determine the recommended dose, and evaluate preliminary efficacy following a single intravenous infusion after lymphodepleting chemotherapy. The study will also assess pharmacokinetics, pharmacodynamics, minimal residual disease (MRD) negativity, objective response rate, progression-free survival, and overall survival in heavily pretreated R/R MM patients.

CT0596: CARsgen Therapeutics

CT0596 is an investigational allogeneic (off-the-shelf) BCMA-targeted CAR T-cell therapy being developed for the treatment of relapsed/refractory multiple myeloma (R/R MM) and other plasma cell malignancies. It is engineered using CARsgen's proprietary THANK-u Plus™ platform with TRAC, B2M, and NKG2A gene knockouts to minimize graft-versus-host disease (GvHD), reduce host immune rejection, and enhance CAR T-cell persistence. Early clinical studies have demonstrated a manageable safety profile with encouraging anti-myeloma activity in heavily pretreated patients, supporting its continued clinical development. CT0596 is currently being evaluated in Phase I clinical trials as a potential off-the-shelf alternative to autologous BCMA-directed CAR T-cell therapies.

Further product details are provided in the report……..

CAR T-Cell Therapy for Multiple Myeloma: Therapeutic Assessment

This segment of the report provides insights about the different CAR T-Cell Therapy for Multiple Myeloma drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in CAR T-Cell Therapy for Multiple Myeloma
• There are approx. 20+ key companies which are developing the therapies for CAR T-Cell Therapy for Multiple Myeloma. The companies which have their CAR T-Cell Therapy for Multiple Myeloma drug candidates in the most advanced stage, i.e. Phase III include, AstraZeneca.

• Phases

DelveInsight’s report covers around 22+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

CAR T-Cell Therapy for Multiple Myeloma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses CAR T-Cell Therapy for Multiple Myeloma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging CAR T-Cell Therapy for Multiple Myeloma drugs.

CAR T-Cell Therapy for Multiple Myeloma Report Insights

• CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

CAR T-Cell Therapy for Multiple Myeloma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing CAR T-Cell Therapy for Multiple Myeloma drugs?
• How many CAR T-Cell Therapy for Multiple Myeloma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T-Cell Therapy for Multiple Myeloma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the CAR T-Cell Therapy for Multiple Myeloma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for CAR T-Cell Therapy for Multiple Myeloma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• AstraZeneca
• Hebei Senlang Biotechnology Inc., Ltd.
• CARsgen Therapeutics
• Gilead Sciences
• AstraZeneca
• Caribou Biosciences, Inc.
• Kelonia Therapeutics
• Immuneel Therapeutics
• OriCell Therapeutics
• HaemaLogiX
• Chongqing Precision Biotech Co., Ltd
• Allogene Therapeutics

Key Products

• AZD0120
• SENL103
• CT0596
• Anitocabtagene autoleucel
• AZD4045
• CB-011
• KLN-1010
• IMN 005
• OriCAR-017
• KMCAR™
• C-4-29
• BCMA/CD70 dual targeted CAR-T cell therapy